11 drugs recalled during March, FDA reports


Pexels.com

Eleven drugs were recalled in March to protect patients from possible harmful defects associated with the products, the U.S. Food and Drug Administration reported.

Such recalls are voluntary actions carried out by drug makers to remove potentially defective medicines from the market, the FDA said. They may be initiated either by the manufacturer or the FDA.

---

Drug Recalls for March

DateBrand NameProduct

Description

Reason / ProblemCompany
March 25LegacyLosartan Potassium USPImpurity foundLegacy Pharmaceutical Packaging
March 22LeopardDietary SupplementUndeclared sildenafilUSA LESS
March 21Blue

Fusion

Capsules marketed as a

dietary supplement for male enhancement

Tainted with sildenafil, tadalafil, desmethyl carbodenafil, dithiodesmethyl carbodenafil, scutellarin and daidzeinAta Int. Inc.
March 18MylanLevoleucovorin Injection, 250 mg/25 mLDue to the presence of

particulate matter identified as copper salts

Mylan Institutional LLC
March 15LegacyLosartan Potassium USPImpurity foundLegacy Pharmaceutical Packaging
March 15HospiraSodium bicarbonate injection USPParticulate matterHospira Inc.
March 5Life-Line tmAdditive for human drinking waterPotentially contaminated with Pseudomonas aeruginosaMcDaniel Life-Line LLC
March 4Apotex Corp.Drospirenone and Ethinyl Estradiol Tablets, USPMay contain defective blistersApotex Corp.
March 1Sunstone OrganicsWhite Vein Kratom and Maeng Da KratomPotential for salmonellaSunstone Organics
March 1Torrent PharmaLosartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide Tablets USPContains

N-Methylnitrosobutyric acid (NMBA)

Torrent Pharmaceuticals Limited
March 1Aurobindo, AcetrisValsartan and Amlodipine and Valsartan tabletsContains

N-nitrosodiethylamine (NDEA),

AurobindoPharma USA Inc.
Source: U.S. Food and Drug Administration

More News

FDA Health News